Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 4.85B +142.3% |
| Revenue (ttm) | 268.09M +60.4% |
| Net Income | 124.45M |
| EPS | 6.13 |
| Shares Out | 20.04M |
| PE Ratio | 39.44 |
| Forward PE | 41.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 280,972 |
| Open | 240.41 |
| Previous Close | 231.27 |
| Day's Range | 230.83 - 247.38 |
| 52-Week Range | 98.89 - 244.00 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 247.29 (+2.28%) |
| Earnings Date | May 7, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $247.29, which is an increase of 2.28% from the latest price.
News
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Ligand Pharmaceuticals Transcript: M&A announcement
The acquisition of XOMA Royalty will double the portfolio size, add seven commercial royalties, and over 100 development-stage programs, driving immediate and long-term earnings growth. The all-cash deal is expected to be accretive from 2026, with significant synergies and no shareholder dilution.
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deli...
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., ...
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown...
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst
Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc (NASDAQ: LGND), citing the distinctive royalty firm offers compelling upside.
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...
Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 48% royalty revenue growth and 42% adjusted EPS increase, driven by strong commercial launches and portfolio expansion. 2026 guidance projects continued double-digit growth, supported by a robust late-stage pipeline and over $1B in deployable capital.
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of $...
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,...
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...
Ligand Pharmaceuticals Transcript: Investor Day 2025
Management outlined a strategy focused on diversified royalty investing, driving strong financial growth and raising five-year royalty CAGR guidance to 23%. Key assets like Filspari, Ohtuvayre, and ZELSUVMI are fueling revenue, while the team and capital base have scaled to support more complex, high-return deals.
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over...
Ligand Pharmaceuticals Transcript: 17th Annual Southwest IDEAS Conference
A diversified royalty aggregator leverages a lean, expert team to invest in over 100 biopharma assets, focusing on high-margin, low-risk cash flows. Recent financials show strong growth, with updated 2024 guidance and a robust five-year outlook driven by new product launches and portfolio expansion.
Ligand Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw record revenue and EPS growth, driven by strong royalty assets and a $53M gain from the Pelthos transaction. Full-year guidance was raised, with robust cash reserves and a $460M convertible note supporting an active investment pipeline.
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) an...
Ligand to Participate in November Investor Conferences
JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 20...
Ligand to Host Investor Day on December 9, 2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17 th Captisol-enabled™ approved product JUPITER, Fla....